Overview
- Trial results presented at the American Diabetes Association and published in The Lancet show once-weekly CagriSema, a fixed-dose mix of the amylin analogue cagrilintide and the GLP-1 drug semaglutide, cut blood glucose more and yielded greater weight loss than semaglutide or placebo.
- REIMAGINE 2, a 68-week phase 3 study of 2,728 adults on metformin with or without SGLT2 inhibitors, found the combination produced larger HbA1c reductions and greater weight loss than semaglutide alone.
- REIMAGINE 3 tested CagriSema as an add-on to basal insulin in 274 people and reported mean HbA1c falling from 8.8% to 6.5% with weight drops up to 12% and no severe hypoglycemia events.
- REIMAGINE 1, in 189 drug‑naïve adults treated for nine months, showed early glucose and weight benefits that investigators say raise the possibility of inducing remission in some patients.
- Study authors report a safety and tolerability profile consistent with prior GLP-1 trials, and they say further sub-analyses and program readouts are under way before regulators and clinicians can assess longer-term use and access.